OnBioVC » R – MID-ATLANTIC

Sequoia Pharma, Inc.: Series C $35M

arubenstein — Wed, 17 Jan 2007 17:47:00 +0000

Sequoia Pharmaceuticals (Gaithersburg, MD) drug developer focused on the treatment of drug-resistant HIV infections, has raised $35M in Series C funding. The deal was led by Wellcome Trust and existing investors Healthcare Ventures, Sofinnova Partners and Aberdare Ventures. The round was also joined by MedImmune Ventures.

VIRxSYS Corp.: Series G $20M

arubenstein — Thu, 14 Dec 2006 04:21:00 +0000

VIRxSYS Corporation (Gaithersburg, MD), who is developing genetic therapies for HIV and cancer, closed a $20M Series G round of financing, the company has raised a total of $87M to date. The financing will be used to support research and clinical programs including VRX496, a gene-based immunotherapy for the treatment of HIV. Phase II clinical trials of VRX496 are underway. Financial backers were not announced.